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ementia is one of the major causes of loss of
autonomy, and the main reason for the institutionaliza-
tion of the elderly.Epidemiological studies conducted in
the last 10 years have shown that the prevalence of
dementia is close to 5% in the population over 65 years
of age.These studies have also shown that its prevalence
increases sharply with age, and as a result of the
expected shift in population demographics,the incidence
and prevalence of dementia are expected to increase
dramatically over the coming decades.The number of
demented patients worldwide is projected to increase
from 24.3 million in 2001 to 81.1 million in 2040.
1
Significantly,the vast majority of new cases are expected
to appear in developing countries.For example,the num-
ber of demented persons in China and India will
increase by 300% during this period.
1 Prevention and
management of dementia are therefore a major public
health challenge in the majority of countries around the
world.
As a general rule, the occurrence of dementia is not a
sudden phenomenon. It is the final stage of cognitive
deterioration,the speed of which varies from one indi-
vidual to the other. However, even in cases where its
development is rapid,the process is measured in terms of
months.Taking into account the life expectancy of indi-
viduals at risk,retarding the development of dementia
for a few months may have important consequences on
the prevalence of dementia.
2
Such expectations have been raised in recent years with
the discovery of a relationship between hypertension and
dementia. Overall, published studies suggest that high
blood pressure increases the risk of cognitive decline and
dementia, and therefore, that lowering blood pressure
might reduce this risk. This paper will review the evi-
dence for this, and will discuss some of the important
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Hypertension is a known risk factor for stroke, and thus
for vascular dementia. However, recent large observa-
tional studies have suggested that high blood pressure
may also play a role in Alzheimer’s disease. The mech-
anisms linking hypertension to Alzheimer’s disease
remain to be elucidated, but white matter lesions seen
on cerebral magnetic resonance imaging appear to be
a good marker of this association. It is not yet clearly
established whether lowering blood pressure reduces
the risk of white matter lesions and dementia, so large
trials dealing with this question are eagerly awaited.
These future trials could confirm the hope that, by low-
ering blood pressure, we may have a preventive treat-
ment for dementia. This issue is of major importance, as
the number of cases of dementia is expected to rise
sharply in the near future.   
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evidence from observational studies
It has been known for decades that there is a direct,causal
relationship between high blood pressure and the risk of
stroke,and therefore the risk of dementia (Figure 1).It is
common knowledge that large strokes or multiple strokes
contribute directly to cognitive decline and to the risk of
dementia, consequently called vascular dementia.
However,it is only in the past 10 years that studies have
reported that hypertension may be related to cognitive
decline and dementia without the occurrence of a stroke.
Hypertension and stroke-related dementia:
a well-established relationship
Hospital- and population-based studies have firmly
established that dementia is more frequent in patients
with stroke than in patients without.
3-8 Cognitive assess-
ment performed 3 months after stroke revealed that 20%
to 30% of patients are demented.
7,9,10 In one of the largest
clinical series of 453 patients who were examined 3
months after their stroke,26% were demented.
11 It is esti-
mated that stroke multiplies the risk of dementia by a
factor of two to five, thus constituting one of the
strongest risk factors for dementia.
3,5,10,12,13The strength of
this association suggests a causal link between stroke and
dementia,although numerous other factors influence this
relationship,some pertaining to the patient—such as age,
level of education, cognitive level before stroke, white
matter lesions on magnetic resonance imaging (MRI),
Apolipoprotein E4 (ApoE4) allele,etc—and others to
the stroke itself—mainly its size,severity,and location.
Interestingly,in the few studies that have included a clas-
sification of dementia, typical vascular dementia repre-
sented only 57%
11 to 64%
7 of all dementias with stroke,
thus suggesting that a significant proportion of stroke-asso-
ciated dementias may be classified as Alzheimer's disease
(AD) or mixed dementia.This was confirmed in popula-
tion-based studies in Rochester and New York,where a
50% to 60% increase in AD in individuals with stroke
compared with those without was observed.
5,14These data
were interpreted as meaning that the occurrence of a
stroke may actually unmask ongoing AD.This hypothesis
was also lent support by studies showing that prestroke
cognition is altered in 15% to 20% of patients with a post-
stroke dementia.
15,16The effect of this interaction between
neurodegenerative factors or lesions and stroke on the risk
of dementia has been demonstrated in the Nun study.
17 In
this autopsy study,participants who had the neuropatho-
logical hallmarks of AD and at least one lacunar stroke
had a risk of clinical dementia multiplied by a factor of
about 20 compared with those with the hallmarks of AD
but no lacunar stroke.
To summarize,even if the relationship between stroke
and dementia is not disputed,it appears that the question
of the type of dementia is more complex than initially
believed.In many cases,poststroke dementia might be
related to pre-existing neurodegenerative lesions.
Conversely,some small and not always clinically notice-
able infarcts may precipitate individuals towards a clin-
ically conspicuous AD.What is not yet understood is the
extent of these phenomena. If they were not so infre-
quent, the relevance of the existing classification of
dementia, based on a clear-cut separation of vascular
dementia and AD,would undoubtedly be questioned.
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Selected abbreviations and acronyms
ACE  angiotensin-converting enzyme
AD Alzheimer's disease
MMSE  Mini Mental State Examination
MRI  magnetic resonance imaging
PROGRESS  Perindopril pROtection aGainst REcurrent 
Stroke Study
SCOPE  Study on COgnition and Prognosis in the
Elderly
SHEP  Systolic Hypertension in the Elderly
Program
Syst-Eur Systolic Hypertension in Europe Trial
WML  white matter lesions
Figure 1. Diagrammatic representation of the consequences of hyper-













?Hypertension and cognitive decline unrelated to stroke
Several studies have shown an inverse association between
blood pressure and cognitive function without the occur-
rence of a stroke (Figure 1). In the Framingham Heart
Study,Elias et al examined cognitive function and mem-
ory performance as related to initial blood pressure mea-
surement over a 12-to 14-year period.
18Among 1702 sub-
jects,cognitive performance was inversely correlated with
initial systolic and diastolic blood pressure readings:the
higher the blood pressure,the lower the cognitive perfor-
mance.In the Honolulu-Asia Aging Study,in which 3735
Japanese-American male subjects living in Hawaii were
enrolled,elevated systolic blood pressure in midlife pre-
dicted future reduced cognitive function.A 10-mm Hg
increase in systolic blood pressure was associated with a
significantly increased risk of both intermediate and poor
cognitive function.This relationship remained after adjust-
ment for stroke, coronary heart disease, and subclinical
atherosclerosis.
19 Our group conducted a longitudinal
study in 1373 older adults (aged 59 to 71 years),the EVA
study,to examine whether baseline hypertension and use
of antihypertensive medication predicted cognitive decline
at a 4-year follow-up assessment.
20We found a relationship
between cognitive decline and a history of hypertension
(systolic blood pressure ≥160 mm Hg or diastolic blood
pressure ≥95 mm Hg),and we also discovered that the risk
was the highest in patients with untreated hypertension.
Hypertensive subjects receiving adequate treatment had
no increased risk of cognitive decline compared with nor-
motensive subjects.
20 In another prospective,longitudinal,
population-based study,it was also found that among 2068
elderly individuals,subjects aged 65 years or older were
more likely to make errors on a mental status question-
naire when their systolic blood pressure taken 9 years ear-
lier was at least 160 mm Hg.
21 Other studies have not
found any association between high blood pressure and
cognitive function.
22-26This inconsistency has been attrib-
uted to the selection of populations investigated,differ-
ences between the methods used to assess cognitive func-
tion,and perhaps a misunderstanding of the synchronicity
in the development of hypertension and cognitive impair-
ment.However,a majority of cross-sectional and longi-
tudinal studies have found a deleterious effect of high
blood pressure on cognition.
27,28
With regard to dementia,several studies have reported a
similar association between high blood pressure and the
risk of dementia.In a longitudinal study in Sweden,a sig-
nificant link was found between the presence of high sys-
tolic and diastolic blood pressures and the development of
dementia 10 to 15 years later.
29 Similar findings were
reported in other studies,such as the Honolulu-Asia Aging
Study,
30 a Finnish study with a 21-year long follow-up,
28 and
the Kaiser Permanente study.
31 In comparison with the
study of simple cognitive decline,there is a greater num-
ber of studies that show no association between dementia
and high blood pressure, and some even suggest that
dementia is associated with low blood pressure.
32,33 This
could be explained,in full-blown dementia,by the neu-
ronal depopulation of deep brain structures involved in
the control of blood pressure or by the apathy of severely
demented individuals who may have lessened their activ-
ity and consequently their blood pressure.
Antihypertensive treatment was sometimes found to be
protective in observational studies. In a community
cohort study of 1810 persons aged 75 years or older,the
prevalence of dementia was significantly lower among
patients being treated for hypertension than among those
not taking antihypertensive medications (P<0.001).
34 In
The Honolulu-Asia Aging Study, early and aggressive
blood pressure control lessened the likelihood of cogni-
tive impairment in later life.
19 Similarly,in the EVA study,
hypertensive subjects receiving adequate treatment had
no increased risk of cognitive decline compared with nor-
motensive subjects.
20
Randomized trials of blood pressure-lowering
drugs on the risk of dementia
Prevention of dementia in stroke patients:
the PROGRESS study
Blood pressure-lowering therapy with the long-acting
ACE inhibitor perindopril combined with the diuretic
indapamide reduces the risk of poststroke dementia by
one third and the risk of severe cognitive decline by
nearly one half, according to the results from the
PROGRESS study (Perindopril pROtection aGainst
REcurrent Stroke Study).
35 PROGRESS was a ran-
domized, double-blind, placebo-controlled trial that
enrolled 6105 men and women, with a mean age of 64
years, with prior stroke or transient ischemic attack
(TIA), from 172 institutions in 10 countries in Asia,
Australia,and Europe.Participants were randomized to
active treatment (n=3051) or placebo (n=3054).
36,37
Active treatment was comprised of perindopril 4 mg
Hypertension and dementia - Tzourio Dialogues in Clinical Neuroscience - Vol 9 . No.1 . 2007
63daily for all participants, along with 2.5 mg daily of the
diuretic indapamide (2 mg in Japan) in patients in whom
a diuretic was neither specifically indicated nor con-
traindicated. The main results of PROGRESS
38 were
that active treatment with perindopril alone or with
indapamide reduced blood pressure by 9/4 mm Hg over
4 years of follow-up,and was associated with an overall
reduction of 28% in the risk of recurrent strokes (the
primary outcome of the study) compared with placebo
(P<.0001 among hypertensive and nonhypertensive
patients with a history of stroke or TIA).Active treat-
ment also reduced the risk of total major vascular events
by 26%. Combination therapy with perindopril plus
indapamide reduced blood pressure by 12/5 mm Hg and
stroke risk by 43%. One of the secondary outcomes of
PROGRESS was dementia and severe cognitive decline.
During the follow-up period of 4 years,dementia (diag-
nosed according to DSM-IV criteria) and severe cogni-
tive decline (a drop of ≥3 points in the Mini Mental State
Examination [MMSE]) were assessed. Median MMSE
score at baseline was 29 (range, 27 to 30); a large pro-
portion of patients (41%) had good cognitive function
(MMSE =30), but 16% had cognitive impairment
(MMSE <26). Over 25% of patients screened positive
for dementia (768 and 812 in the active treatment and
placebo groups,respectively).After independent assess-
ment by an expert in dementia, 410 patients were iden-
tified as having dementia (equivalent to an incidence of
17 per 1000 patient-years), of whom 108 had dementia
preceded by a stroke.Cognitive decline was identified in
610 patients (incidence of 25 per 1000 patient-years),of
whom 134 had had a previous stroke.Overall,there was
a nonsignificant (12% (range, -8% to 28%]) reduction
in the risk of dementia in the active treatment group.
Evaluation within the two dementia subgroups (with or
without prior stroke), however, showed a significant
reduction of 34% (P=.03) in the risk of dementia with
active treatment in patients with prior stroke and a 1%
reduction in patients without prior stroke.A similar pat-
tern was observed for cognitive decline, with an overall
risk reduction of 19% (P=0.01) with active treatment
overall,but a significant risk reduction of 45% (P<.001)
with active treatment in patients with prior stroke and a
9% reduction in patients without stroke. Combination
therapy was more effective in reducing the risk of
dementia (23%) than monotherapy (-8%), although
there was no statistical difference between regimens (P
for homogeneity, 0.1) In patients with no cognitive
impairment at baseline (84%),active treatment reduced
the risk of dementia by 31%, but there was no effect in
patients with cognitive impairment at baseline (-3%).
Among the patients without cognitive impairment at
baseline, a 50% reduction in the risk of dementia was
observed in those with prior stroke, compared with a
16% reduction in those without stroke.
Trials in hypertensive patients without stroke
Four large-scale randomized controlled trials using blood
pressure-lowering agents have reported the effects of
treatment on the risk of dementia or measures of cogni-
tive function.
39-42 While three trials identified no clear
effect of the treatment under study on the risk of demen-
tia
39,42 or on cognitive function,
40,42 one reported a signifi-
cant benefit from treatment on the risk of dementia.
41
In the UK Medical Research Council’s trial in older
hypertensive patients, there was no apparent effect of
treatment on any measure of cognitive impairment.
40
Similarly, in the Systolic Hypertension in the Elderly
Program (SHEP),
39 active treatment had no discernible
effect on the incidence of dementia.However,a recent
reanalysis suggests that differential dropout rates in
active treatment and placebo groups may have intro-
duced a bias leading to this conclusion.
43
The most exciting data with regard to the prevention of
dementia by lowering blood pressure have come from
the Syst-Eur trial.
41,44 This trial was a double-blind,
placebo-controlled trial of nitrendipine,a calcium antag-
onist, with the addition of enalapril, hydrochloroth-
iazide,or both,titrated or combined as needed to reduce
systolic blood pressure by at least 20 mm Hg so as to
reach a target of <150 mm Hg in over 4000 patients aged
over 60 years.Syst-Eur included a dementia substudy in
a subset of 2418 patients (1180 in the placebo group and
1238 in the active-treatment group).At the end of the
trial,which was stopped prematurely after a median fol-
low-up of 2 years because the preplanned interim analy-
ses demonstrated a significant benefit for stroke, 1861
patients remained on double-blind treatment; 60%
received nitrendipine alone,32% received nitrendipine
plus enalapril, and 15% received these two drugs plus
hydrochlorothiazide. Dementia was diagnosed in 21
cases in the placebo group and in 11 cases in the active
treatment group, resulting in a 50% reduction in the
incidence of dementia in the active arm. Interestingly,
the majority of dementia cases were of AD and not vas-
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64cular dementia.This remarkable finding should, how-
ever, be interpreted with caution because of the small
number of outcome events.As a result of this limited
power, the possible impact of blood-pressure lowering
can extend from having no effect to a massive 76%
reduction in the risk of dementia. Moreover, the large
number of participants who were lost to follow-up fur-
ther undermines the validity of the study.
In another randomized trial,the Study on Cognition and
Prognosis in the Elderly (SCOPE),no treatment effect
on cognition was observed.
42,45 SCOPE was a prospective,
double-blind, randomized, parallel-group study con-
ducted from 1997 to 2002,in which 4964 patients aged 70
to 89 years,with SBP 160 to 179 mm Hg and/or DBP 90
to 99 mm Hg (untreated or thiazide-treated) and MMSE
test score ≥24,were assigned to receive candesartan or
placebo with open-label active antihypertensive therapy
added if necessary. No significant difference was
observed in mean final MMSE score between the can-
desartan group (final score 28.0) and the control group
(final score 27.9) (P=.20),and the proportion of patients
who had a significant cognitive decline or who developed
dementia was not different in the two treatment groups.
42
However,due to ethical concerns,this study was finally
redesigned to compare effects between the candesartan-
based treatment and the usual antihypertensive therapy
regimens and,as a result,the reduction in blood pressure
was limited (Table I).
In summary,there are still very few large trials that have
assessed the prevention of dementia by blood pressure-
lowering drugs (Table I).PROGRESS is the only study
that has assessed the risk of dementia in patients with
stroke. It reports a reduction in the risk of poststroke
dementia and no clear effect on the risk of dementia
without stroke.
35The most convincing trial to date in non-
stroke patients,Syst-Eur,is hampered by the relatively
small number of cases.In an open extension of the fol-
low-up the results of the main study were confirmed,with
a doubling of the number of cases.
46 However, special
caution is needed to interpret these results because of the
limitations and the potential biases of an open follow-up.
A large and specifically designed trial is therefore needed
to confirm and to quantify the reduction of the risk of
dementia by blood pressure-lowering drugs in hyperten-
sive subjects.
Mechanisms of the relationship between
hypertension and cognition when there is no
stroke: the white matter lesion hypothesis
The mechanisms by which high blood pressure can oper-
ate at the cerebral level are widely unknown.Recently,
the development of cerebral imaging and more particu-
larly of MRI has shown that silent strokes, and more
broadly, white matter lesions (WML) are common, in
particular in patients with hypertension and in the elderly
(Figure 2).
WML: definition and risk factors
WML are areas of high signal on T2-weighted images
located in the cerebral white matter, and among them,
silent strokes may be singled out by their low signal on
T1-weighted images.These lesions share the same risk
factors as stroke, mainly age
47-53 and hypertension.
54-58
Some studies have shown that a sustained high blood
pressure level increases the risk of WML,suggesting that
there was a dose-response relationship.
56,57 The level of
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Table I. Main randomized trials on antihypertensive drugs and the risk of dementia. SBP, systolic blood pressure; DBP, diastolic blood pressure; 
BB, β-blocker; CCB, calcium channel blocker; ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin II type1 receptor blocker;
NS, nonsignificant
Study Sample size SBP/DBP Drug tested Duration of  Reduction in P value




39 4736 -12/4 mm Hg BB ± diuretic 4.5 years 16%N S
Syst-Eur
41 2418 - 8.3/3.8 mm Hg CCB ± ACE ± diuretic 2 years 50% (0-76%) 0.05
PROGRESS
35 6105 - 9 / 4 mm Hg ACE ± diuretic 4 years All dementia: 12% (8-28%) NS
Dementia with recurrent  0.03
stroke: 34% (3-55%)
SCOPE
42 4964 - 3.2 / 1
.6 mm Hg ARB 4 years 7% NSblood pressure also seems to play a role, the highest
blood pressure values being associated with the higher
grades of WML.
59This aspect of dose-response in terms
of duration and level of exposure is an important argu-
ment to suggest that the relationship between high blood
pressure and WML may be causal,as it is for stroke.
The mechanisms leading to WML are not yet fully under-
stood,but degeneration of small-caliber arteries (arte-
riosclerosis) has been consistently found,
60-62 as well as a
reduced cerebral blood flow
63-66; these are both known
consequences of high blood pressure on the brain.
67-69
Therefore, it is generally assumed that WML are a
marker of a chronic state of cerebral ischemia in hyper-
tensive patients.
Consequences of WML
One general hypothesis is that the accumulation of
lesions in the white matter can lead to a subsequent cog-
nitive deterioration by disconnection of cortico-subcor-
tical pathways.Several studies have indeed shown that
WML are associated with cognitive impairment
47,52,53,59,70-72
and with dementia
73-75 (Figure 1). Several aspects are,
however, still poorly understood: What is the relative
importance of the location,type,and extent of WML on
the risk of cognitive impairment? Are there major effect
modifiers on this relationship, such as the ApoE poly-
morphism and education level? Are WML associated
with cortical atrophy? If yes,as suggested by some stud-
ies,
76-78 what is the relative importance of both regarding
the risk of cognitive impairment? Some of these ques-
tions have already been addressed, though very often
with small series of selected patients.Further,the eval-
uation of WML is highly variable across studies,and no
clear consensus has yet emerged to date.
WML have also been found to be associated with gait
disturbances and a higher risk of falls
79-83 and symptoms
resembling Parkinson’s disease,
84-86 as well as a higher risk
of stroke
87,88 and depression.
89-93 It is therefore not an over-
statement to say that WML—at least when their load is
elevated—are guilty of accelerating aging of the brain.
Trying to control their aggravation is therefore an impor-
tant goal.
Preventing the evolution of WML:
the PROGRESS-MRI study
This was a substudy of the PROGRESS trial described
above.In this substudy,
94 we analyzed data gathered from
192 people (average age 60) recruited in 10 centers in
France. Each participant had a brain MRI at baseline,
which was repeated after an average follow-up of 36
months.At baseline, a neuroradiologist examined each
scan and determined that 42% of participants had no
WML; 26% had mild WML, 13% had moderate WML
and 19% had severe WML.Eighty-nine patients were in
the active treatment arm,and 103 were on placebo.About
half of the subjects were already being treated for high
blood pressure. At the time of the second MRI, blood
pressure had significantly decreased by an average of 11.2
mm Hg systolic and 4.3 mm Hg diastolic.In order to limit
the variability between the two exams attributable to the
MRI technique (position of the head of the patient,dif-
ferent slicing,etc),we performed an automatic registration
and segmentation of both MRI exams after their storage
in an Object-Oriented Relational Database.By doing so,
we made both exams as comparable as possible,and an
independent observer,blinded to the data and the order
of the MRI exams,would be able to compare them pre-
cisely and detect and measure any new lesion.Overall,the
risk of new WML was reduced by 43% in the treatment
group compared with the placebo group,although the dif-
ference did not reach significance (P=0.10).The volume of
new areas of WML in the treatment group was one fifth
of that in the untreated group (0.4 cubic mm versus 2 cubic
mm,P=0.012).The most striking difference was noted in
the 27 patients who already had severe WML at the first
MRI.In these subjects,no new areas of abnormality devel-
oped in those in the treatment group,compared with an
Clinical research
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Figure 2. White matter lesions on cerebral MRI. Cerebral MRI of two
women 67 years of age without (on the left) and with (on the
right) hypertension. The subject with hypertension had several
deep and periventricular white matter lesions (arrows). MRI,
magnetic resonance imaging67
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average of 7.6 cubic millimeters of new WML in patients
on placebo (P=0.001).
This study showed,for the first time,that it is possible to
limit the development of WML by lowering blood pres-
sure, even though the number of subjects was rather
small.As result of this low power, there was not suffi-
cient power to study simultaneously the impact of treat-
ment on cognition in this sample. Further studies are
needed to confirm these results in larger and indepen-
dent samples. Also, studies should be performed in
patients who do not have a past history of cerebrovas-
cular disease.
Tentative conclusions and future prospects
There is no doubt that high blood pressure is associated
with cognitive deterioration and dementia, indepen-
dently of the occurrence of a stroke.Conflicting results
come in part from the various ways of testing cognition
and defining cognitive decline,and the lack of precisely
diagnosing dementia in its early stage.Another,and yet
unsolved, issue is the modification of this relationship
with age.It is likely that the risk of cognitive deteriora-
tion related to high blood pressure decreases with
increasing age.A similar modification of the risk with age
is observed in the relationship between hypertension and
stroke.Further,there appears to be spontaneous lower-
ing of blood pressure at the advanced stage of dementia,
probably through neuronal depopulation in the centers
regulating blood pressure,which renders the relationship
even more complex. Finally, the true relative risk of
dementia associated with hypertension is probably rela-
tively modest compared with other stronger risk factors
for dementia like age, education, and the ApoE poly-
morphism.Therefore,some degree of fluctuation is not
unexpected when estimating this risk,and some of the
controversial results could thus be explained.
Despite these difficulties, clarifying this relationship
remains of major importance.With the ageing of our soci-
eties,we are facing an epidemic of dementia for which we
have no curative or preventive treatment.In this context,
even a modest reduction in the risk would have important
consequences.Moreover,even if high blood pressure is
associated with a moderate relative risk of dementia,its
very high prevalence means that the risk of dementia
attributable to high blood pressure may be high,and that
improved control of hypertension may translate into a
dramatic reduction in the number of cases of dementia.
95
Unanswered questions
What is the true magnitude of the relationship? 
The data are still insufficient,and we definitively need
more population-based studies in the elderly in order to
accurately estimate the risk of dementia attributable to
high blood pressure and other vascular factors.Some of
the existing large population-based studies in this
domain should also combine their efforts with a view to
producing an exact measure of this risk.
Is it possible to identify individuals or groups at high
risk? 
It is likely that the effect of high blood pressure on the
brain varies dramatically between individuals, even
among hypertensive patients.Those at high risk of hyper-
tension-related cognitive decline or dementia would ben-
efit the most from accurate control of their hypertension.
Again,these high-risk groups can be properly identified
only in large observational studies with a long follow-up.
Are WML an appropriate marker of the poor tolerance
of high blood pressure by the brain? 
The answer is most likely positive,but several issues on
the true mechanisms linking WML to cognition remain
unresolved,in particular regarding their characteristics:
location,size,signal intensity,etc.In addition,what is not
well understood either is the natural history of WML.
Results from a few studies suggest that some patients
have a rapid increase in their WML load and that they
would be those who have a higher risk of severe cogni-
tive decline,but this remains to be confirmed.
These questions are important, and must be answered
to improve our understanding of the relationship
between hypertension and dementia.However,it is also
possible to state that we have enough data at hand to set
up a clinical trial on the reduction of the risk of demen-
tia by lowering blood pressure. This trial, specifically
designed to study dementia, should be very large so as
to produce a significant number of cases with the longest
follow-up as possible. Among some other important
variables, the investigators of this trial would have to
choose the type of patients who should be included:old-
old patients are more exposed to a short-term risk of
dementia, but blood pressure-lowering drugs might beClinical research
68
less effective in these patients than in young-old patients
who are,in turn,less prone to dementia.Demonstrating
a treatment effect in the youngest hypertensive patients
would require a much larger number of patients or a
longer follow-up.The choice of the type of drug could
also be important,as it is not yet known if the protective
effect observed is uniquely due to the lowering of blood
pressure or if there is a class effect of a given antihy-
pertensive agent.A meta-analysis
96 suggests that calcium
antagonists are more effective than other drugs in
reducing the risk of stroke in hypertensive patients.
Whether this apparent class effect could also apply to
the risk of dementia is an open question. Finally, an
important decision is whether or not to perform MRI
scans on part of the sample or on the entire sample.The
data from MRI exams would be of great value in con-
firming the impact of the blood pressure-lowering drug
on the brain and in understanding the variability of this
impact across categories of patients.
The study of the epidemiology of dementia and cogni-
tive deterioration has now completed its first phase,
which began in the early 1990s and provided extensive
descriptive data.Given the growing epidemiological and
clinical evidence for the implication of vascular factors
in the risk of dementia,the identification and control of
these factors in middle-aged and elderly individuals may
represent an important approach for decreasing the inci-
dence of dementia.This could be demonstrated properly
only through large randomized trials. One can expect
that,as has occurred with coronary heart disease,the sec-
ond phase of the study of the epidemiology of dementia
will be devoted to such trials. ❏
Hipertensión, déficit cognitivo y demencia:
una perspectiva epidemiológica
La hipertensión arterial es un factor de riesgo conocido
para el accidente vascular encefálico y en consecuen-
cia para la demencia vascular. Sin embargo, extensos
estudios observacionales recientes han sugerido que la
presión arterial elevada puede jugar también un papel
en la Enfermedad de Alzheimer. Los mecanismos que
relacionan la hipertensión con la Enfermedad de
Alzheimer aun deben ser dilucidados, pero las lesiones
en la sustancia blanca que se han observado en la reso-
nancia magnética cerebral parecen ser buenos marca-
dores de esta asociación. Aun no está claramente esta-
blecido que la reducción de la presión arterial
disminuya el riesgo de lesiones en la sustancia blanca
y de demencia, por lo que se espera con gran ilusión
que grandes ensayos clínicos traten de aclarar esta pre-
gunta. Estos futuros ensayos clínicos podrían confirmar
la esperanza que, al reducir la presión arterial, se
pueda contar con un tratamiento preventivo para la
demencia. Este tema es de la mayor importancia ya
que se espera que el número de casos de demencia
aumente marcadamente en un futuro cercano.
Hypertension, déclin cognitif et démence :
une perspective épidémiologique
L’hypertension est un facteur de risque connu d’acci-
dent vasculaire cérébral et donc pour la démence vas-
culaire. Cependant, le rôle éventuel d’une pression
artérielle élevée dans la maladie d’Alzheimer a été
évoqué dans des études récentes observationnelles
portant sur de grands effectifs. Les mécanismes liant
l’hypertension à la maladie d’Alzheimer demandent
à être approfondis mais des lésions de la substance
blanche vues à l’IRM (imagerie par résonance magné-
tique) semblent être un bon marqueur de cette asso-
ciation. Il n’est pas encore clairement établi que la
baisse de la pression artérielle diminue le risque de
lésions de la substance blanche et de démence. De
larges études consacrées à cette question sont émi-
nemment attendues. Elles pourraient confirmer l’es-
poir d’un traitement préventif de la démence par
diminution de la pression artérielle. Il s’agit d’un pro-
blème d’importance majeure du fait que le nombre
de cas de démence est amené à augmenter considé-
rablement dans un futur proche.
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